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PTCL constitutes a rare but highly ag-
gressive group of non-Hodgkin lym-
phomas that respond poorly to standard 
chemotherapy regimens, with long-
term  survival  of  <30%  (Rodríguez   
et al., 2009). The molecular underpin-
nings of these heterogeneous lympho-
mas are largely unknown, and because 
of  this,  fully  representative  animal 
model systems are not currently avail-
able. Recently, a recurrent transloca-
tion was identified in a subset of PTCL 
that  fuses  the  inducible  T  cell  kinase  
(ITK) gene on chromosome 5 with 
the spleen tyrosine kinase (SYK) gene 
on chromosome 9 to form the ITK-
SYK fusion gene (Streubel et al., 2006). 
The t(5;9)(q33;q22) is found in 18% 
of  all  PTCL–not  otherwise  specified 
(NOS) cases and represents one of the 
few recurrent translocations identified 
in this disease. In this issue, Pechloff  
et al. describe the first mouse model 
for the t(5;9)-associated malignancy.
Insertion of the human ITK-SYK 
fusion  cDNA  into  the  Rosa26  locus 
preceded by a loxP-flanked stop cas-
sette generated an inducible construct. 
Rosa-lsl-ITK-SYK mice were crossed 
with CD4-Cre and CD19-Cre trans-
genic mice to activate ITK-SYK ex-
pression in T and B cells, respectively. 
However,  ITK-SYK  expression  pro-
moted disease only when expressed in 
T cells, with the resulting malignancy 
mimicking a disseminated PTCL. The 
ITK-SYK–expressing  T  cells  showed 
responsiveness to SYK inhibitors, open-
ing the door to the possibility of tar-
geted  therapy  using  FDA-approved 
inhibitors of this kinase.
Although the t(5;9)(q33;q22) trans-
location is rare among the non-Hodgkin 
lymphomas, the presence of a recurrent 
translocation gives insight into the sig-
naling cascades that drive PTCL disease. 
This paradigm has been successfully 
exploited in the myeloid malignancies, 
where  a  large  percentage  of  all  acute 
myeloid leukemia (AML) cases are asso-
ciated with recurrent translocations. The 
animal models that have been developed 
using the myeloid leukemia–associated 
translocation genes have been invalu-
able in understanding the molecular and 
biochemical signals critical for disease   
development and maintenance, and have 
led to significant advances with regard 
to the therapeutic targeting of these 
leukemias  (Cammenga,  2005;  Fathi   
et al., 2010).
Previously,  laboratory  studies  of 
PTCL used a limited range of cell lines 
from select groups of PTCL cases that 
may or may not be representative of 
the disease entity as a whole. Mouse 
modeling  depended  on  animals  ex-
pressing transgenes encoding oncogenes 
such as MYC, BCL-2, PIM, and RAS, 
or lacking genes encoding tumor sup-
pressors such as p53, PTEN, and ATM. 
However, these genetic manipulations 
represent  common  molecular  lesions 
present  in  many  different  types  of   
cancer, and are not specific to PTCL 
(Tarantul,  2004).  Some  hints  as  to   
underlying  pathogenic  mechanisms   
and prognostic signatures have been 
gleaned from gene expression profil-
ing of PTCL specimens, but overall the 
results have been difficult to interpret   
(de Leval et al., 2009). The heteroge-
neous nature of this disease and the 
lack of well-defined associated molec-
ular lesions have significantly impeded 
progress toward a better understanding 
and treatment of PTCL. The success of 
this group in establishing a representa-
tive model for PTCL-NOS can be ex-
pected to result in improved knowledge 
of PTCL and identification of rele-
vant targets for therapy.
ITK is a member of the TEC family 
of  nonreceptor  protein  tyrosine  ki-
nases and plays a critical role in activa-
tion through the T cell receptor (TCR; 
Prince et al., 2009). In T cells lacking 
ITK, TCR-induced phospholipase C 
(PLC)- phosphorylation, Ca
2+ release, 
NFAT transcription factor activation, 
and  mitogen-activated  protein  kinase 
signaling are significantly impaired, re-
sulting  in  a  reduced  proliferative  re-
sponse and little interleukin-2 release. 
Although  the  TEC  family  members 
RLK and TEC are also expressed in   
T cells, ITK appears to play a nonre-
dundant role in TCR signaling. The 
structural domains of ITK give insight 
into its regulation and activity (Joseph 
and  Andreotti,  2009).  ITK  has  an   
N-terminal pleckstrin homology (PH) 
domain that is important for its re-
cruitment  to  the  plasma  membrane   
in  response  to  phosphatidylinositol 
generation  by  phosphatidylinositol- 
3-kinase. A TEC homology domain 
that defines the family is found adjacent 
to the PH domain, but has ill-defined 
functions.  ITK  also  contains  SH3   
and SH2 domains, both of which are 
likely critical for autoinhibition of acti-
vation and subsequent protein–protein 
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PH (and/or TEC homology) domains 
of different TEC family members that 
affect function in ways we do not yet 
understand. It is also possible that the 
ITK-SYK fusion requires endogenous 
ITK expression to efficiently transmit 
activation signals to downstream sub-
strates  such  as  PLC-,  SLP-76,  and 
LAT. In this scenario, the fusion pro-
tein would be substituting for TCR- 
associated  ZAP-70  function  rather 
than ITK function to initiate the signal-
ing cascades for T cell activation. Because 
B cells do not express much endogenous 
ITK, this could explain the lack of effect 
on B cell function. These are all testable 
hypotheses and are important consider-
ations  in  regard  to  future  therapeutic 
options for the disease.
The CD4-Cre x Rosa-lsl-ITK-SYK 
model used here is an elegant approach 
that circumvents potential side effects, 
but has its drawbacks. Foremost, using 
CD4-Cre induces ITK-SYK expression 
at the CD4
+CD8
+ stage of thymocyte 
development, which is highly unlikely 
to be the physiological target cell for 
transformation. PTCL-NOS is a disease 
of adults with a median age of 60 yr, 
and these individuals present primarily 
with a disease of mature CD4
+ T cells 
(Cotta and Hsi, 2008). One possible way 
to circumvent activation at this early 
stage is to use an inducible Cre such as 
Cre-ER (estrogen receptor). This would 
allow investigators to activate Cre (and 
therefore fusion gene expression) in the 
adult animals upon injection of tamoxi-
fen into the mouse.
Another drawback of this model is 
the simultaneous activation of the onco-
gene in thousands or millions of cells, a 
state that is never found in nature. This 
could be why the disease manifests so 
broadly, in actuality more like a leukemia/
lymphoma than a PTCL, given the abun-
dance of tumor cells in the peripheral 
blood of the mice. It is interesting to 
note that the CD19-Cre mouse that was 
developed  by  this  group,  and  which 
did not result in B cell malignancies, 
gave rise to late T cell lymphomas, pre-
sumably because of leaky activation of 
Cre in some T cells in the CD19-Cre 
mouse. These tumors were definitively 
shown to have arisen from single T cells 
In  this  study,  expression  of  ITK-
SYK in T cells resulted in a fully pene-
trant T cell lymphoma with a median 






arose, and extensive infiltration of these 
cells into tissues throughout the mouse 
was evident. The malignancy was read-
ily transferred to secondary mice, and 
the lymphomas were clonal in nature; 
the latter finding is perhaps not surpris-
ing, given the long latency of disease.   
T cells expressing ITK-SYK displayed 
an activated surface phenotype, with 
constitutive localization of both ITK-
SYK and endogenous ITK to lipid rafts. 
Using  kinase-dead  and  PH  domain 
point mutant ITK-SYK fusion proteins, 
Pechloff et al. (2010) showed that lipid 
raft localization and kinase activity were 
required for the T cell activation phe-
notype. Interestingly, a previous gene 
array  study  found  that  PTCL-NOS   
patient samples have an expression pro-
file that resembles activated but not qui-
escent T cells, demonstrating that this 
mouse model may accurately reproduce 
the  activation  state  found  in  primary 
human PTCL (Piccaluga et al., 2007). 
The constitutive localization of the fusion 
protein to lipid rafts is likely caused by 
the loss of the SH3 and SH2 domains   
of ITK, which are believed to be criti-
cal for autoinhibition of the molecule 
(Joseph and Andreotti, 2009). Without 
the  allosteric  inhibition  of  self-associ-
ated SH3 and SH2 molecules, the PH 
domain becomes available for interac-
tions  with  phosphatidylinositols  in 
lipid rafts.
Somewhat  surprisingly,  ITK-SYK 
expression in B cells elicited essentially 
no phenotype, and the fusion protein 
was not significantly localized to lipid 
rafts in B cells. Because the PH domain 
of ITK is highly conserved in the B cell– 
expressed TEC family counterpart BTK, 
one would assume that the phosphatidyl-
inositols  generated  by  phosphatidyl-
inositol-3-kinase in B cells would be able 
to efficiently recruit the ITK PH domain, 
but this may not be the case. These data 
raise the question of whether a BTK-
SYK  fusion  would  efficiently  trans-
form B cells but not T cells, and whether 
there are particular modifications in the 
interactions at the plasma membrane 
upon ITK activation. In cells with t(5;9), 
the SH3, SH2, and kinase domains of 
ITK are missing from the translocation 
product, and it is likely that the loss of 
ITK autoinhibition plays an important 
role in the constitutive activation of the 
resulting ITK-SYK fusion protein.
SYK and ZAP-70 constitute a sec-
ond  family  of  nonreceptor  tyrosine   
kinases  that  are  intricately  involved   
in receptor signal transduction in lym-
phocytes (Palacios and Weiss, 2007).   
Although SYK is of primary importance 
in B cell receptor signaling, and ZAP-70 
in TCR signaling, both proteins appear 
to play important roles during thymo-
cyte development, and significant re-
dundancy is evident in numerous mature 
hematopoietic cell types. In particular, 
SYK appears to play an important role in 
immune receptor signaling in inflamma-
tory cells and is a prime target for phar-
maceutical companies interested in drug 
development for autoimmune and in-
flammatory diseases. SYK and ZAP-70 
have tandem N-terminal SH2 domains 
that interact in a cooperative fashion with 
phosphorylated ITAM motifs on immu-
noreceptor molecules (Turner et al., 
2000). The regulation of SYK activity is 
complex and probably cell type depen-
dent, but in general SYK is more readily 
activated than ZAP-70 and is less de-
pendent on other kinases, such as SRC 
family  tyrosine  kinases,  for  function 
(Chu et al., 1998; Tsang et al., 2008). 
SYK has several conserved tyrosine resi-
dues located in the interdomain between 
the  SH2  and  the  C-terminal  kinase 
domains. These are sites of SYK auto-
phosphorylation that can also be phos-
phorylated by LYN and potentially by 
other  SRC  family  members.  Upon 
phosphorylation, these residues serve as 
docking sites for downstream signaling 
components of immune receptor activa-
tion, including LCK, PLC-, VAV, and 
CBL, which serve to potentiate and 
dampen receptor signaling (Turner et al., 
2000). Most of these tyrosine residues 
are  retained  in  the  ITK-SYK  fusion 
product and potentially play a role in the 
interesting  biological  phenotypes  that 
are induced by fusion protein expression 
in T and B cells.JEM VOL. 207, May 12, 2010 913
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by surface staining for TCR variable chain 
usage. This model, although very slow 
and financially untenable for this reason, 
could be more representative of what oc-
curs in a human patient. The malignan-
cies that arose in these models may be of 
particular interest for molecular and bio-
chemical analysis. One wonders whether 
the cooperating events that led to final 
malignancy in the CD19-Cre mouse are 
similar to those that occurred in the CD4-
Cre tumors. This would be most readily 
analyzed using unsupervised hierarchical 
clustering of gene expression array data.
As more data are generated using gene 
expression arrays and deep sequencing   
of tumor samples, it will be interesting 
to determine whether immunoreceptor 
activation is a common theme among 
diverse tumors of the hematopoietic sys-
tem. As the authors point out, diseases 
including diffuse large B cell lympho-
mas, chronic lymphocytic leukemias, 
mucosa-associated lymphoid tissue lym-
phomas  and  follicular  lymphoma  all 
present with aberrant antigen receptor 
signaling  pathways  (Küppers,  2005; 
Davis et al., 2010). In a study published 
last month, a phase 1/2 clinical trial using 
the Syk inhibitor fostamatinib disodium 
in patients with various recurrent B cell 
non-Hodgkin lymphomas found signifi-
cant objective response rates (Friedberg 
et al., 2010). Aberrant expression of acti-
vated SYK has also been found in >90% 
of PTCL, a striking finding that begs the 
question of whether this signaling path-
way is the dominant signal in this malig-
nancy and the t(5;9) translocation is an 
alternative mechanism to the same end 
(Feldman et al., 2008). Constitutive SYK 
activation has recently been implicated 
in AML as well, using a gene expres-
sion–based  high-throughput  screen  to 
identify small molecules with signifi-
cant antileukemia activity (Hahn et al., 
2009). The exact pathobiology is un-
clear, but it is possible that SYK couples 
with the immunoreceptors expressed in 
these different hematopoietic cells and 
elicits an activation signal that promotes 
the aberrant proliferation of the malig-
nant cells. This opens the way to addi-
tional  preclinical  and  clinical  trials  of 
SYK inhibitors, as well as more broad 
inhibitors  of  immune  receptor  signal 
transduction. The availability of this new 
mouse model is a good starting point.
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